Drugs Made In America Acquisition Corp. (DMAAU) Cash from Financing Activities (2025)
Drugs Made In America Acquisition's (DMAAU) quarterly Cash from Financing Activities came in at $130600.0 in Q4 2025, up 133.2% on a QoQ basis from $56003.0 in Q3 2025.
Drugs Made In America Acquisition Corp. (DMAAU) Cash from Financing Activities (2025) Analysis & Trends
Drugs Made In America Acquisition (DMAAU) has 1 years of Cash from Financing Activities data on file, last reported at $130600.0 in Q4 2025.
- Quarterly Cash from Financing Activities changed N/A year-over-year to $130600.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $231.7 million (changed N/A YoY) and the FY2025 annual result came in at $231.7 million, up 133351.97% from the prior year.
- Cash from Financing Activities advanced to $130600.0 in Q4 2025, from $56003.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $231.4 million in Q1 2025 to a low of $56003.0 in Q3 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 130,600.00 |
| Dec 31, 2025 | 130,600.00 |
| Sep 30, 2025 | 56,003.00 |
| Sep 30, 2025 | 56,003.00 |
| Jun 30, 2025 | 106,554.00 |
| Jun 30, 2025 | 106,554.00 |
| Mar 31, 2025 | 231.40 Mn |
| Mar 31, 2025 | 231.40 Mn |